Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State.

[1]  S. Wakeman,et al.  Use of promethazine, gabapentin and clonidine in combination with opioids or opioid agonist therapies among individuals attending a syringe service program. , 2020, The International journal on drug policy.

[2]  E. Vittinghoff,et al.  Effects of Mirtazapine for Methamphetamine Use Disorder Among Cisgender Men and Transgender Women Who Have Sex With Men: A Placebo-Controlled Randomized Clinical Trial. , 2019, JAMA psychiatry.

[3]  B. Leroux,et al.  Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. , 2019, Journal of substance abuse treatment.

[4]  J. Duchin,et al.  Engaging an Unstably Housed Population with Low-Barrier Buprenorphine Treatment at a Syringe Services Program: Lessons Learned from Seattle, Washington , 2019, Substance abuse.

[5]  M. Olfson,et al.  Development of a Cascade of Care for responding to the opioid epidemic , 2019, The American journal of drug and alcohol abuse.

[6]  P. Korthuis,et al.  A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. , 2018, Drug and alcohol dependence.

[7]  Caleb J. Banta-Green,et al.  Interest in Getting Help to Reduce or Stop Substance Use Among Syringe Exchange Clients Who Use Opioids , 2018, Journal of addiction medicine.

[8]  R. Bruno,et al.  Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. , 2018, Drug and alcohol review.

[9]  N. Lee,et al.  Pharmacotherapy for amphetamine dependence: A systematic review. , 2018, Drug and alcohol dependence.

[10]  M. Sullivan.  Depression Effects on Long-term Prescription Opioid Use, Abuse, and Addiction , 2018, The Clinical journal of pain.

[11]  M. McDonell,et al.  A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies , 2018, Substance abuse and rehabilitation.

[12]  Stuart S. Washington,et al.  Low-threshold extended-release naltrexone for high utilizers of public services with severe alcohol use disorder: A pilot study. , 2018, Journal of substance abuse treatment.

[13]  K. Feder,et al.  Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. , 2017, Drug and alcohol dependence.

[14]  M. Stitzer,et al.  Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. , 2017, Journal of substance abuse treatment.

[15]  B. Grant,et al.  Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States. , 2016, The Journal of clinical psychiatry.

[16]  M. Maracy,et al.  The Effect of Buprenorphine on Methamphetamine Cravings , 2015, Journal of clinical psychopharmacology.

[17]  L. Cooley,et al.  HIV Infection, risk, prevention, and testing behaviors among persons who inject drugs—National HIV Behavioral Surveillance: injection drug use, 20 U.S. cities, 2012 , 2015 .

[18]  H. Connery.  Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions , 2015, Harvard review of psychiatry.

[19]  R. Garfein,et al.  Patterns of Drug Use, Risky Behavior, and Health Status Among Persons Who Inject Drugs Living in San Diego, California: A Latent Class Analysis , 2015, Substance use & misuse.

[20]  C. Cunningham,et al.  Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. , 2015, Journal of substance abuse treatment.

[21]  L. Ray,et al.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. , 2014, Drug and alcohol dependence.

[22]  J. Maxwell.  A New Survey of Methamphetamine Users in Treatment: Who They are, Why They Like “Meth,” and Why They Need Additional Services , 2014, Substance use & misuse.

[23]  E. Vittinghoff,et al.  Mirtazapine to reduce methamphetamine use: a randomized controlled trial. , 2011, Archives of general psychiatry.

[24]  R. Clark,et al.  The evidence doesn't justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. , 2011, Health affairs.

[25]  K. Brady,et al.  Distinctive characteristics of methamphetamine users presenting at public clinics: steep rise in South Carolina, United States, 2000-2005. , 2011, Drug and alcohol dependence.

[26]  L. Amato,et al.  Pharmacological treatment for depression during opioid agonist treatment for opioid dependence. , 2010, The Cochrane database of systematic reviews.

[27]  B. Marshall,et al.  Addiction Treatment and Stable Housing among a Cohort of Injection Drug Users , 2010, PloS one.

[28]  F. Greenway,et al.  Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. , 2009, The Journal of clinical endocrinology and metabolism.

[29]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[30]  R. Booth,et al.  Predictors of Methamphetamine Injection in Out-of-Treatment IDUs , 2009, Substance use & misuse.

[31]  N. Lee,et al.  A systematic review of cognitive and behavioural therapies for methamphetamine dependence. , 2008, Drug and alcohol review.

[32]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[33]  R P Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.

[34]  R. White.  Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. , 2000, Addiction.